CASE REPORT article

Front. Pediatr., 26 August 2022

Sec. Pediatric Infectious Diseases

Volume 10 - 2022 | https://doi.org/10.3389/fped.2022.959419

Successful treatment of pleural empyema and necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus infection following influenza A virus infection: A case report and literature review

  • 1. Clinical School of Pediatrics, Tianjin Medical University, Tianjin, China

  • 2. Department of Pulmonology, Tianjin Children’s Hospital, Tianjin University Children’s Hospital, Tianjin, China

  • 3. Institute of Pediatrics, Tianjin Children’s Hospital, Tianjin University Children’s Hospital, Tianjin, China

Abstract

With the rapid increase in the number of infections, children with Staphylococcus aureus (S. aureus) infection secondary to Influenza A virus (IAV), appear to have a great possibility of causing severe complications and illness. Despite some cases and research findings regarding the death of children with IAV and S. aureus, coinfection included, there were few details about successful treatment of pleural empyema and necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) infection following IAV. In this case report, we describe the clinical symptoms and treatment of a teenager with pleural empyema and necrotizing pneumonia related to S. aureus secondary infection who was initially infected by IAV. This case highlights the importance of early recognition and application of thoracoscopy for this potentially fatal pleural empyema caused by MRSA and IAV coinfection. We conclude that this is a significant case that contributes to raising awareness regarding rarely occurring severe respiratory infections by MRSA in a child with normal immune function after IAV. In addition, further studies are needed to explore risk factors for IAV coinfection with S. aureus.

Introduction

Retrospective studies of samples from the four pandemic influenza outbreaks of the last century have identified secondary bacterial infections as the fatal cause of co-morbidity and co-mortality, which reportedly manifested especially in the following week after viral infection symptoms are manifested, in 40–95% of influenza A -associated cases (). IAV infections are associated with increased susceptibility to secondary bacterial infections, such as S. aureus and Streptococcus infections, wherein morbidity and mortality increase significantly (). Children with IAV and S. aureus coinfection appear to have a great possibility of causing severe complications, and the mortality rate is very high as well. However, the details about the successful treatment of complications caused by coinfection of IAV and S. aureus have been rarely reported. In the present study, we report a unique case of pleural empyema and necrotizing pneumonia related to MRSA in a 13-year-old boy who was initially infected by IAV. Meanwhile, based on previous literature reports, we summarized the clinical characteristics and treatment of IAV and S. aureus coinfection.

Case description

A previously healthy 13-year-old boy was hospitalized with a three-day history of cough and fever. He was diagnosed with IAV infection in the local hospital. On admission, he was in respiratory distress and complained of left-sided chest pain. Laboratory indicators were shown in Table 1. His oxygen saturation level was 89–94% with an oxygen supply and he could not even lie down. The computed tomography (CT) scan of his chest showed atelectasis and a small amount of pleural effusion (Figure 1A). He was provided with oxygen support, anti-infection therapy and nutritional support. A diagrammatic representation of the treatment and outcome was presented in Figure 2.

TABLE 1

Date of examinationWBC (×109/L; 4.0–10.0)Neutrophils (%; 45–77)CRP (mg/L; 0–8)Hb (g/L; 110–160)PLT (×109/L; 100–300)PCT (ng/ml)IL-6 (pg/ml)D-dimer (mg/L)CK (U/L; 50–310)CKMB (U/L; 0–24)LDH (U/L; 120–300)AST (U/L; 15–40)
1st6.98.1412.33135188NANANANANANANA
4th5.2388237.1126117NANANA5082035533
5th5.7891.2202.815111549.12424.6NANormalNANANA
6th6.658264.41241638.66NA0.2NANA458NA
8th11.777214.7136248NANANANANANANA
11th19.278917.91504260.531.590.4NANA355NA
13th18.868245135299NANANANANANANA
16th11.267766.2129283NANANANANANANA
18th7.967422.2111298NANANANANANANA
19th7.056610.41163180.0913.440.9NANANANA
22th4.6960<2.5114299NANANANANANANA

Changes of various laboratory values.

WBC, white blood cell; PCT, procalcitonin; CRP, c-reactive protein; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; CK, creatine Kinase; CKMB, creatine kinase Mb isoenzyme.

FIGURE 1

FIGURE 2

The following day, the patient was not doing well and developed a stridor; hence, the decision was made to perform a flexible bronchoscopy with bronchoalveolar lavage (BAL) under ECG monitoring and respiratory oxygen support after employing local anesthesia (Figure 1B). Because the patient’s severe pneumonia progressed rapidly and even endangered his life, an early and accurate etiological diagnosis was very important for the implementation of pathogen-specific treatment. Therefore, the next-generation sequencing analysis from BAL fluid was performed, and it indicated S. aureus as the infectious pathogen residing in the patient’s lungs. Blood culture for microbial infection was also found positive for S. aureus. On the fourth day of hospitalization, the chest X-ray showed no improvement, so the bronchoscope was continued to be used for BAL. Tracheal aspirate showed heavy growth of MRSA sensitive to linezolid, vancomycin, and rifampicin. Meanwhile, it was resistant to tetracyclines and quinolones.

Unfortunately, the patient was very ill, remained pyrexial (38.8°C) and developed a left-sided pyopneumothorax on day 8 of hospitalization with recurring fever, and the body temperature increased to 38.8°C. The patient complained of chest pain related to breathing abnormality, accompanied by apparent breath-holding. B-scan ultrasound and CT imaging (Figure 1C) of thorax revealed massive bilateral pleural effusions and multiple cavities in the left lung. Based on the laboratory and imaging diagnostic investigations, thoracentesis was performed on the patient’s left chest, and the chest tube was placed on the same side.

Even after 12 days of hospitalization and treatment, the patient’s condition did not improve due to poor drainage of empyema as a result of cellulose and thick pus accumulation. The patient underwent thoracoscopy to diagnose and treat pleural effusion (Figure 1D). After thoracoscopic investigations of the pleural cavity, the lung surface was cleared of the thick yellow moss-like layer of pus, and the left chest cavity was repeatedly flushed until the outflow was clear. At the end of the surgical procedure, the light bloody liquid could be seen in the chest bottle, and the chest tube was connected to the closed thoracic drainage system to prevent further pleural effusions.

On the 19th day of hospitalization, the chest drainage tube was removed. His cough condition was improved, and his breathing rate was stable without the occurrence of shortness of breath. The patient was discharged without any complaints of breathing discomfort. The patient was followed up for a chest X-ray examination after ten months of hospital discharge. The prognosis was good and the patient was in good physical condition.

Discussion

Influenza is considered as a known potential risk factor for Staphylococcal diseases (). There are strong and consistent pieces of evidence of epidemiologically and clinically important interactions between the influenza virus and secondary bacterial respiratory pathogens (). A study in the United States () showed that S. aureus was the most common bacterial pathogen (44%) among the 36 children who died of bacterial co-infection reported during the 2004–2007 influenza season, while MRSA accounted for 60%. The complication of co-infection progresses rapidly, and children cannot get accurate and timely treatment, which is one of the reasons for its high mortality rate.

There are several hypothetical mechanisms of bacterial co-infection secondary to influenza virus infection. It is reported that the influenza virus can increase the adhesion of bacteria by destroying the epithelial layer of the tracheobronchial tree and neuraminidase activity (, ). At the same time, Panton-Valentine leukocidin (PVL) is a pore-forming cytotoxin produced by S. aureus genes, acting synergistically to induce a strong lytic effect on host defense cells, notably with poly-morphonuclear leucocytes but especially on neutrophils (). Previously infected influenza virus can enhance the proinflammatory and cytotoxic effects of PVL on neutrophils. Disintegration of the epithelial airway results in hemorrhage and tissue damage, which leads to the development of necrotizing pneumonia (). In addition, nasal carriage of S. aureus is a significant risk factor for secondary staphylococcal pneumonia in IAV (). Therefore, children with a history of S. aureus infection should be more alert to the risk of IAV and S. aureus co-infection. Finelli et al. found that compared with children without S. aureus infection, children with S. aureus infection were more prone to pneumonia and acute respiratory distress syndrome during the influenza season ().

We reviewed 16 clinical reports of IAV and S. aureus coinfection; however, five of them lack detailed clinical information (Table 2). Reviewing the literature of 16 children with IAV and S. aureus co-infection, we can find that S. aureus is almost always characterized by MRSA. Most of these children are older than 10 years old, which is consistent with the result of Finelli et al. (). Complications in these children mainly include sepsis, empyema, DIC, pneumothorax, lung abscess, emphysema, necrotizing pneumonia, and so on. However, most detection of virulence factors of S. aureus were missing. Two cases presented PVL (+) and one presented PVL (−). A study suggested that an early confirmed presence of the PVL toxin is particularly important in choosing antibiotics and administrating immunoglobulin that inhibits PVL toxin release in early stage (). Notably, the application of bronchoscopy was important for early detection of the patient’s respiratory conditions. However, bronchoscopic results have rarely been reported and utilized in treating children with S. aureus co-infection that is secondary to IAV. In this case, we removed the obstruction of the trachea and lung with the assistance of bronchoscopy findings. Moreover, we could wash the diseased area of alveoli through alveolar lavage and subsequently analyzed the BAL fluid for bacterial infection. Bronchoscopy has also been reported in the case of Sharp et al. (). Copious cloudy secretions, fibrinous debris, and patchy plaques were found in the main bronchi and distal trachea. We should pay more attention to the application opportunity of bronchoscope. Thoracoscopy was also the key for this potentially fatal pleural empyema caused by MRSA and IAV coinfection when patient developed pleural adhesion and multiple cavities. In addition, the application of drugs was also critical. In our case, we covered the positive cocci in the initial treatment. We timely adjusted antibiotics by detecting the drug resistance of S. aureus, which effectively controlled the S. aureus infection. Due to the application of flexible bronchoscopy, thoracoscopy and adequate anti-infective treatment, we could successfully relieve the patient’s uncomfortable respiratory conditions, and let the patient be discharged within 3-weeks of hospitalization.

TABLE 2

ReferencesCases in articleAge at the diagnosisSexDuration of hospitalization (days)ComplicationDrugOutcomeS. aureus drug resistanceVirulence factor
Boettger et al.()121-month-oldNA3Sepsis, atelectasis, and pleural effusionOrotracheal tube, central venous catheter insertion, and ventilatory supportOseltamivir, Ceftriaxone, and clarithromycinDeathMRSAicaA, icaB, icaD, SeiO, hla and hlb(+); PVL and TSST-1(−)
Sharp et al.()19-year-oldMale12Sepsis and circulatory collapseECMO, bronchoscopyVancomycin, meropenem, and enteral oseltamivirDeathMRSANA
Pugh()15-year-oldMale30 moreEmpyemaChest tube insertionVancomycin, clindamycin, and cefepimeRecoveryMRSANA
Thomas et al. ()113-year-oldFemale8Acute necrotizing tracheobronchitisNoneAmoxicillin and codeineDeathPenicillin susceptibleNA
Obando et al.()112-year-oldMale28Empyema and pneumothoraxThorascopic surgery and chest tube insertionCeftriaxone, vancomycin, clarithromycin, linezolid, and oseltamivirRecoveryMRSAPVL(+), ACME(+)
Barrett et al.()117-year-oldMale17SepsisNoneClarithromycin and co-amoxiclavRecoveryMSSAPVL(+)
Thomas et al.()18-month-oldMale25Pleural effusionChest tube insertionAmpicillin sodium, gentamicin sulfate, and nafcillin sodiumRecoveryNANA
Tanaka et al.()111-month-oldFemale37Empyema, DICThoracentesis and thoracoscopic decorticationOseltamivir phosphateRecoveryMSSANA
CDC ()310-year-oldMale3Hypotension and hypoxiaEndotracheal intubationCeftriaxone and vancomycinDeathMRSANA
14-year-oldMale2Sepsis, DIC, and necrotizing pneumoniaEndotracheal intubationClarithromycin, penicillin, oseltamivir, ceftriaxone, and vancomycinDeathMRSANA
8-year-oldFemale20Renal and hepatic failure, a subpulmonic abscess, respiratory distress, and sepsisEn dotracheal intubationAzithromycin, dexamethasone, and ceftriaxoneDeathMRSANA
CDC()514-year-oldFemale19NANAOseltamivirDeathMRSANA
13-year-oldMale5NANAOseltamivirDeathMRSANA
15-year-oldMale2NANANoneDeathNANA
9-year-oldFemale15NANAOseltamivirDeathMRSANA
15-year-oldMale7NANAOseltamivirDeathMRSANA

The clinical characteristics and results of the literature review of the IAV and S. aureus coinfection.

In conclusion, due to the synergistic pathogenic effects between the influenza virus and coinfecting respiratory bacteria, we should raise awareness regarding the rarely occurring severe respiratory infections by S. aureus, following influenza for early diagnosis and rapid recovery from respiratory complications in children. In addition, this study suggests a need for further research about risk factors of secondary S. aureus infection of IAV.

Statements

Data availability statement

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

Written informed consents were obtained from the parents for publication of this report.

Author contributions

TZ and XL cared for patients. YZ and LD collected the data. CH and JZ drafted the article. WG and YX revised it for intellectual content. CH and CC approved the final completed article. All authors read and approved the final manuscript.

Funding

This work was supported by the Tianjin Natural Science Foundation (Grant no. 21JCYBJC00460) and Tianjin Science and Technology Planning Project (Grant no. 20JCZXJC00170), the Science and Technology Training Project of Tianjin Health Committee (Grant no. RC20020), and General Project of Tianjin Children’s Hospital (Grant no. Y2020013). We are grateful for the financial support from the “Tianjin Medical Key Discipline (Specialty) Construction Project” (Grant no. TJYXZDXK-040A).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Summary

Keywords

Staphylococcus aureus, influenza A virus, pleural empyema, necrotizing pneumonia, bronchoscopy

Citation

Han C, Zhang T, Zhao Y, Dong L, Li X, Zheng J, Guo W, Xu Y and Cai C (2022) Successful treatment of pleural empyema and necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus infection following influenza A virus infection: A case report and literature review. Front. Pediatr. 10:959419. doi: 10.3389/fped.2022.959419

Received

01 June 2022

Accepted

05 August 2022

Published

26 August 2022

Volume

10 - 2022

Edited by

Hans Van Rostenberghe, Universiti Sains Malaysia (USM), Malaysia

Reviewed by

Frieder Schaumburg, University of Münster, Germany; Arturo Solis-Moya, Dr. Carlos Sáenz Herrera National Children’s Hospital, Costa Rica

Updates

Copyright

*Correspondence: Wei Guo, Yongsheng Xu, Chunquan Cai,

†These authors have contributed equally to this work and share first authorship

This article was submitted to Pediatric Infectious Diseases, a section of the journal Frontiers in Pediatrics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics